Evotec 566480, wohin geht die Reise??? (Seite 6482)
eröffnet am 12.01.07 11:23:52 von
neuester Beitrag 19.04.24 18:00:01 von
neuester Beitrag 19.04.24 18:00:01 von
Beiträge: 81.629
ID: 1.104.790
ID: 1.104.790
Aufrufe heute: 19
Gesamt: 16.120.526
Gesamt: 16.120.526
Aktive User: 0
ISIN: DE0005664809 · WKN: 566480 · Symbol: EVT
13,200
EUR
-0,90 %
-0,120 EUR
Letzter Kurs 19.04.24 Tradegate
Neuigkeiten
| Evotec Aktien jetzt im kostenlosen Demokonto handeln!Anzeige |
19.04.24 · Felix Haupt Anzeige |
18.04.24 · Shareribs Anzeige |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 1,1060 | +30,10 | |
| 1,5400 | +25,71 | |
| 12,400 | +23,26 | |
| 7,0700 | +16,86 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7255 | -15,15 | |
| 1,3500 | -15,63 | |
| 0,8700 | -20,18 | |
| 4,6600 | -28,75 | |
| 0,6021 | -35,26 |
Beitrag zu dieser Diskussion schreiben
Feedback
24.01.2012
FRANKFURT (dpa-AFX Analyser) - Die Commerzbank hat Evotec auf "Buy" mit einem Kursziel von 3,40 Euro belassen.
Das Hamburger Biotechnologie-Unternehmen straffe mit der vollständigen Übernahme des Konkurrenten DefeloGen seine Unternehmensstruktur weiter, schrieb Analyst Volker Braun in einer Studie vom Dienstag.
dpa-AFX Analysen
FRANKFURT (dpa-AFX Analyser) - Die Commerzbank hat Evotec auf "Buy" mit einem Kursziel von 3,40 Euro belassen.
Das Hamburger Biotechnologie-Unternehmen straffe mit der vollständigen Übernahme des Konkurrenten DefeloGen seine Unternehmensstruktur weiter, schrieb Analyst Volker Braun in einer Studie vom Dienstag.
dpa-AFX Analysen
http://www.thefastertimes.com/diabetes/2012/01/09/diapep277-…
Diapep277: A Landmark Discovery in Diabetes Treatment
January 9, 2012 Jessica Apple
My mother was diagnosed with Multiple Sclerosis (MS) when I was five-years-old. At the
time, there were no effective treatments for the disease. My mother tried every medication
doctors prescribed, an experimental surgery, and even non-conventional therapies. Everything
failed. I tried to help her too, using the tools I had as a child – hope, prayers, and my
imagination. I imagined ways to make her better. And I hoped and prayed with all of my
might that she would stop seeing two of everything, that she would stop shaking, and that she
would be able to walk and talk again. MS is an autoimmune disease, and the concept of
autoimmunity was incomprehensible to me. Why would a body do that to itself? Why can’t
we make it stop?
My mother’s case, unlike a lot of cases of MS, had almost no remissions. Her condition
worsened until her death in 1989. Less than two years after she died, I met Mike, the man who
would become my husband. With Mike I began to build a new life, a good life. My obsessive
thinking about autoimmunity moved to the background of my mind until Mike started to lose
weight and was always thirsty.
Six months later, twenty pounds lighter, with blurred vision and numb feet, Mike was
diagnosed with type 1 diabetes, an autoimmune disease which destroys the body’s insulin
producing beta cells. We hardly knew what that meant, but we did know a diabetes cure was
nowhere in sight. Thankfully, unlike my mother’s MS, diabetes was treatable. In fact, Mike’s
doctor told him that there was a drug in clinical trials that might be able to stop the progression
of diabetes. Stop the progression. Though not in the same context, I’d been waiting to hear
those words for most of my life. They sounded too good to be true and they filled me with
hope. We asked no questions. Mike underwent a number of tests after which he was accepted
into the clinical trial for a drug known as Diapep277.
Diapep277 was discovered in 1990 by Professor Irun Cohen and his team at the Weizmann
Institute’s Department of Immunology. They were studying the mechanism by which the
immune system attacks and destroys the insulin producing beta cells in the pancreas. In mouse
studies they discovered that heat shock protein 60 (HSP60) was involved in the attack. HSP60
is a ubiquitous protein, part of a highly conserved family of intracellular chaperones, but with a
special location in insulin-secretory granules of beta cells. HSP60, Cohen found, works like an
antigen, that is, it triggers the T-cells in the immune system to attack. Cohen’s team also found
that a small peptide fragment of HSP60, p277, works as a signal to the immune system to stop
the immune attack on the beta cells, thereby preventing the progression of diabetes. Cohen and
his team were led to p277, he told me, by studying the responses of T-cells and antibodies to
HSP60 in mice that spontaneously develop a form of type 1 diabetes.
When Mike enrolled in the Phase II trail of Diapep277, he was told it was a potential diabetes
vaccine. This notion of vaccine was somewhat confusing. Mike, after all, had type 1 diabetes.
Diapep277 wasn’t going to prevent it like the chicken pox vaccine prevents chicken pox. But
the notion of a vaccine is more complex than that. “The immune system, like the brain, learns
from experience,” said Cohen. “A vaccine is a signal or set of signals that teaches the immune
system how to respond to a particular situation. We could call Diapep a ‘therapeutic vaccine’ –
probably it would be clearer to call it a specific modulator of the immune system – a signal that
helps the immune system to make desirable decisions in how it should relate to the body.”
Mike’s Diapep277 trial took place in 2002-2003. The study coordinator told him the
participants were divided into three groups – high dose recipients, low dose recipients, and a
placebo group. Then, Mike did not know which group he was in. He now knows he did
receive Diapep277. Throughout the study, doctors monitored Mike closely. They were
checking for residual beta cell function by a measurement of C-peptide (C-peptide is a protein
produced along with insulin, and its presence in the body is a sign of insulin secretion, or beta
cell function.) In order to measure beta cell function, Mike was given glucagon injections and
then blood was drawn to learn his body’s response to the glucagon. The study also measured
his HbA1c. “What was most surprising was the lack of side effects,” says Dr. Mariela Glandt
who led a follow-up trial to Mike’s under Prof. Itamar Raz at Hadassah Hosptial in Jerusalem.
“Patients had no complaints.”
Phase II results were promising and a combined analysis of all the adult phase II studies
revealed that DiaPep277 significantly inhibits the decline in stimulated C-peptide secretion,
thus preserving endogenous insulin secretion, or in simple terms, it slows the progression of
type 1 diabetes.
In 2007, Andromeda Biotech Ltd., a then newly formed wholly owned subsidiary of Clal
Biotechnology Industries, purchased the Diapep277 program. Two years later, Teva
Pharmaceutical took an equity position in Andromeda. Teva licensed worldwide rights to
DiaPep277 from Andromeda Biotech and invested $170 million in the company last year to
fund a clinical trial to confirm earlier results for DiaPep277. (Coincidentally, for me, Teva’s
longtime blockbuster drug has been Copaxone, for the treamtment of MS.)
In November 2011, Andromeda Biotech announced Phase III study results equally, if not more
promising, than the Phase II results. The new results from patients who were treated with
DiaPep277 showed that the study has met its primary endpoint- significant preservation of Cpeptide
levels demonstrated in patients treated with DiaPep277 compared to the placebo arm.
The study also achieved a key secondary endpoint, showing that a greater proportion of
DiaPep277 treated patients maintained good metabolic control compared to the placebo,
measured by HbA1c levels equal or less than 7% at the end of the study. “The results I have
seen thus far are better than I expected,” said Cohen. “Large clinical trials have so many
confounding variables that even treatments that are effective can fail to reach statistical
significance. In this case, all the declared endpoints seem to have been achieved.”
For scientists and researchers involved in a clinical trial, achieving declared endpoints is indeed
a success. The patient, however, doesn’t necessarily measure success in the same way. Mike
wears an insulin pump, checks his blood sugar ten times a day, and battles both episodes of
hyper and hypoglycemia. “I ate rice last night and woke up with a blood sugar of 200, despite
taking insulin,” Mike said. “This morning I went out for a one-hour run and my blood sugar
stayed at 190 the entire time.”
If Diapep277 did anything to slow down the progression of Mike’s diabetes, it was never
noticeable. If it will help in the long-term, we don’t know. Over the years, Mike’s study hasn’t
followed him. And we wonder how long the effects of the Diapep277 injections lasted. I asked
Cohen about this. “The effect seems to need boosting every three months or so,” he said.
Also interesting to note is that a 2007 study showed that in children, treatment with Diapep277
“appears to have no beneficial effect in preserving beta-cell function or improving metabolic
control.” Cohen said a more thorough analysis of the data indicates that there is a positive
response in the children who do not carry the most decisive susceptibility genes. “Apparently,
the disease progresses too quickly for Diapep to help in the children who have a more intense,
accelerated course of beta cell destruction. I would like to believe that the solution will be to
detect and treat persons early in the course of the autoimmune reaction, before the loss of beta
cells become irreversible.”
The key, then, if Diapep277′s continuing trials prove successful, will be to identify the right
people and treat them at the right time- as early in the disease process as possible. But the
development of screening tests is a complicated and expensive process. “I’d been sick for more
than six months when I was diagnosed with diabetes,” Mike says. My fasting blood sugar was
over 400. My HbA1c was 15.7%. Maybe I was too far gone to be helped by Diapep. Maybe if
I’d received the injections as soon as I started to feel thirsty, there would have been a noticeable
difference.”
Whether Diapep277 will develop into a treatment for type 1 diabetes remains to be seen.
What’s already clear is that Cohen and his team have made a landmark discovery in that
they’ve found a way to treat the underlying cause of the disease, something insulin replacement
therapy doesn’t do. And what’s especially promising is that Diapep277 has shown remarkable
safety. “I don’t know if Diapep helped,” Mike said. “But it certainly hasn’t hurt.”
Jessica Apple is co-founder and editor-in-chief of ASweetLife. She writes the blog The Natural
Diabetic.
Grüße
Diapep277: A Landmark Discovery in Diabetes Treatment
January 9, 2012 Jessica Apple
My mother was diagnosed with Multiple Sclerosis (MS) when I was five-years-old. At the
time, there were no effective treatments for the disease. My mother tried every medication
doctors prescribed, an experimental surgery, and even non-conventional therapies. Everything
failed. I tried to help her too, using the tools I had as a child – hope, prayers, and my
imagination. I imagined ways to make her better. And I hoped and prayed with all of my
might that she would stop seeing two of everything, that she would stop shaking, and that she
would be able to walk and talk again. MS is an autoimmune disease, and the concept of
autoimmunity was incomprehensible to me. Why would a body do that to itself? Why can’t
we make it stop?
My mother’s case, unlike a lot of cases of MS, had almost no remissions. Her condition
worsened until her death in 1989. Less than two years after she died, I met Mike, the man who
would become my husband. With Mike I began to build a new life, a good life. My obsessive
thinking about autoimmunity moved to the background of my mind until Mike started to lose
weight and was always thirsty.
Six months later, twenty pounds lighter, with blurred vision and numb feet, Mike was
diagnosed with type 1 diabetes, an autoimmune disease which destroys the body’s insulin
producing beta cells. We hardly knew what that meant, but we did know a diabetes cure was
nowhere in sight. Thankfully, unlike my mother’s MS, diabetes was treatable. In fact, Mike’s
doctor told him that there was a drug in clinical trials that might be able to stop the progression
of diabetes. Stop the progression. Though not in the same context, I’d been waiting to hear
those words for most of my life. They sounded too good to be true and they filled me with
hope. We asked no questions. Mike underwent a number of tests after which he was accepted
into the clinical trial for a drug known as Diapep277.
Diapep277 was discovered in 1990 by Professor Irun Cohen and his team at the Weizmann
Institute’s Department of Immunology. They were studying the mechanism by which the
immune system attacks and destroys the insulin producing beta cells in the pancreas. In mouse
studies they discovered that heat shock protein 60 (HSP60) was involved in the attack. HSP60
is a ubiquitous protein, part of a highly conserved family of intracellular chaperones, but with a
special location in insulin-secretory granules of beta cells. HSP60, Cohen found, works like an
antigen, that is, it triggers the T-cells in the immune system to attack. Cohen’s team also found
that a small peptide fragment of HSP60, p277, works as a signal to the immune system to stop
the immune attack on the beta cells, thereby preventing the progression of diabetes. Cohen and
his team were led to p277, he told me, by studying the responses of T-cells and antibodies to
HSP60 in mice that spontaneously develop a form of type 1 diabetes.
When Mike enrolled in the Phase II trail of Diapep277, he was told it was a potential diabetes
vaccine. This notion of vaccine was somewhat confusing. Mike, after all, had type 1 diabetes.
Diapep277 wasn’t going to prevent it like the chicken pox vaccine prevents chicken pox. But
the notion of a vaccine is more complex than that. “The immune system, like the brain, learns
from experience,” said Cohen. “A vaccine is a signal or set of signals that teaches the immune
system how to respond to a particular situation. We could call Diapep a ‘therapeutic vaccine’ –
probably it would be clearer to call it a specific modulator of the immune system – a signal that
helps the immune system to make desirable decisions in how it should relate to the body.”
Mike’s Diapep277 trial took place in 2002-2003. The study coordinator told him the
participants were divided into three groups – high dose recipients, low dose recipients, and a
placebo group. Then, Mike did not know which group he was in. He now knows he did
receive Diapep277. Throughout the study, doctors monitored Mike closely. They were
checking for residual beta cell function by a measurement of C-peptide (C-peptide is a protein
produced along with insulin, and its presence in the body is a sign of insulin secretion, or beta
cell function.) In order to measure beta cell function, Mike was given glucagon injections and
then blood was drawn to learn his body’s response to the glucagon. The study also measured
his HbA1c. “What was most surprising was the lack of side effects,” says Dr. Mariela Glandt
who led a follow-up trial to Mike’s under Prof. Itamar Raz at Hadassah Hosptial in Jerusalem.
“Patients had no complaints.”
Phase II results were promising and a combined analysis of all the adult phase II studies
revealed that DiaPep277 significantly inhibits the decline in stimulated C-peptide secretion,
thus preserving endogenous insulin secretion, or in simple terms, it slows the progression of
type 1 diabetes.
In 2007, Andromeda Biotech Ltd., a then newly formed wholly owned subsidiary of Clal
Biotechnology Industries, purchased the Diapep277 program. Two years later, Teva
Pharmaceutical took an equity position in Andromeda. Teva licensed worldwide rights to
DiaPep277 from Andromeda Biotech and invested $170 million in the company last year to
fund a clinical trial to confirm earlier results for DiaPep277. (Coincidentally, for me, Teva’s
longtime blockbuster drug has been Copaxone, for the treamtment of MS.)
In November 2011, Andromeda Biotech announced Phase III study results equally, if not more
promising, than the Phase II results. The new results from patients who were treated with
DiaPep277 showed that the study has met its primary endpoint- significant preservation of Cpeptide
levels demonstrated in patients treated with DiaPep277 compared to the placebo arm.
The study also achieved a key secondary endpoint, showing that a greater proportion of
DiaPep277 treated patients maintained good metabolic control compared to the placebo,
measured by HbA1c levels equal or less than 7% at the end of the study. “The results I have
seen thus far are better than I expected,” said Cohen. “Large clinical trials have so many
confounding variables that even treatments that are effective can fail to reach statistical
significance. In this case, all the declared endpoints seem to have been achieved.”
For scientists and researchers involved in a clinical trial, achieving declared endpoints is indeed
a success. The patient, however, doesn’t necessarily measure success in the same way. Mike
wears an insulin pump, checks his blood sugar ten times a day, and battles both episodes of
hyper and hypoglycemia. “I ate rice last night and woke up with a blood sugar of 200, despite
taking insulin,” Mike said. “This morning I went out for a one-hour run and my blood sugar
stayed at 190 the entire time.”
If Diapep277 did anything to slow down the progression of Mike’s diabetes, it was never
noticeable. If it will help in the long-term, we don’t know. Over the years, Mike’s study hasn’t
followed him. And we wonder how long the effects of the Diapep277 injections lasted. I asked
Cohen about this. “The effect seems to need boosting every three months or so,” he said.
Also interesting to note is that a 2007 study showed that in children, treatment with Diapep277
“appears to have no beneficial effect in preserving beta-cell function or improving metabolic
control.” Cohen said a more thorough analysis of the data indicates that there is a positive
response in the children who do not carry the most decisive susceptibility genes. “Apparently,
the disease progresses too quickly for Diapep to help in the children who have a more intense,
accelerated course of beta cell destruction. I would like to believe that the solution will be to
detect and treat persons early in the course of the autoimmune reaction, before the loss of beta
cells become irreversible.”
The key, then, if Diapep277′s continuing trials prove successful, will be to identify the right
people and treat them at the right time- as early in the disease process as possible. But the
development of screening tests is a complicated and expensive process. “I’d been sick for more
than six months when I was diagnosed with diabetes,” Mike says. My fasting blood sugar was
over 400. My HbA1c was 15.7%. Maybe I was too far gone to be helped by Diapep. Maybe if
I’d received the injections as soon as I started to feel thirsty, there would have been a noticeable
difference.”
Whether Diapep277 will develop into a treatment for type 1 diabetes remains to be seen.
What’s already clear is that Cohen and his team have made a landmark discovery in that
they’ve found a way to treat the underlying cause of the disease, something insulin replacement
therapy doesn’t do. And what’s especially promising is that Diapep277 has shown remarkable
safety. “I don’t know if Diapep helped,” Mike said. “But it certainly hasn’t hurt.”
Jessica Apple is co-founder and editor-in-chief of ASweetLife. She writes the blog The Natural
Diabetic.
Grüße
Evotec AG: 'Squeeze-out' bei DeveloGen AG erfolgreich vollzogen
Evotec AG: 'Squeeze-out' bei DeveloGen AG erfolgreich vollzogen
DGAP-News: Evotec AG / Schlagwort(e): Squeeze-Out Evotec AG: 'Squeeze-out' bei DeveloGen AG erfolgreich vollzogen
24.01.2012 / 07:27
Hamburg, Deutschland - 24. Januar 2012: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) gab heute den erfolgreichen Abschluss des DeveloGen 'Squeeze-out' bekannt. Mit diesem Verfahren hat Evotec die verbleibenden DeveloGen-Aktien der Minderheitsaktionäre erworben. Evotec ist nun 100%er Eigentümer der DeveloGen AG. Die DeveloGen-Minderheitsaktionäre werden eine Abfindung von 12,75 EUR pro Aktie erhalten, somit beläuft sich die gesamte Abfindungssumme auf insgesamt etwa 180,000 EUR.
Im Jahr 2010 hatte Evotec 99.4% der DeveloGen-Aktien übernommen. Nachfolgend wurde ein 'Squeeze-out'-Verfahren eingeleitet, um die verbleibenden 0.6% der Aktien zu erhalten, die sich im Besitz von rund 250 Minderheitsaktionären befanden. Am 8. November 2011 stimmte die Hauptversammlung der DeveloGen AG dem 'Squeeze-out'-Verfahren zu. Ein vom Landgericht Hannover ernannter unabhängiger Prüfer hatte zuvor den Preis pro Aktie von 12,75 EUR bestätigt.
Mit der Eintragung des Beschlusses im Handelsregister wurde Evotec zum alleinigen Eigentümer der DeveloGen AG, welche in Evotec (Göttingen) umbenannt wurde.
Kontakt Evotec AG: Dr. Werner Lanthaler, Vorstandsvorsitzender, Tel.: +49.(0)40.56081-242, werner.lanthaler@evotec.com
24.01.2012 Veröffentlichung einer Corporate News/Finanznachricht, übermittelt durch die DGAP - ein Unternehmen der EquityStory AG. Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen. Medienarchiv unter http://www.dgap-medientreff.de und http://www.dgap.de
Sprache: Deutsch Unternehmen: Evotec AG Manfred Eigen Campus / Essener Bogen 7 22419 Hamburg Deutschland Telefon: +49 (0)40 560 81-0 Fax: +49 (0)40 560 81-222 E-Mail: info@evotec.com Internet: www.evotec.com ISIN: DE0005664809 WKN: 566480 Börsen: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
Ende der Mitteilung DGAP News-Service
http://www.finanznachrichten.de/nachrichten-2012-01/22511540…
Evotec AG: 'Squeeze-out' bei DeveloGen AG erfolgreich vollzogen
DGAP-News: Evotec AG / Schlagwort(e): Squeeze-Out Evotec AG: 'Squeeze-out' bei DeveloGen AG erfolgreich vollzogen
24.01.2012 / 07:27
Hamburg, Deutschland - 24. Januar 2012: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) gab heute den erfolgreichen Abschluss des DeveloGen 'Squeeze-out' bekannt. Mit diesem Verfahren hat Evotec die verbleibenden DeveloGen-Aktien der Minderheitsaktionäre erworben. Evotec ist nun 100%er Eigentümer der DeveloGen AG. Die DeveloGen-Minderheitsaktionäre werden eine Abfindung von 12,75 EUR pro Aktie erhalten, somit beläuft sich die gesamte Abfindungssumme auf insgesamt etwa 180,000 EUR.
Im Jahr 2010 hatte Evotec 99.4% der DeveloGen-Aktien übernommen. Nachfolgend wurde ein 'Squeeze-out'-Verfahren eingeleitet, um die verbleibenden 0.6% der Aktien zu erhalten, die sich im Besitz von rund 250 Minderheitsaktionären befanden. Am 8. November 2011 stimmte die Hauptversammlung der DeveloGen AG dem 'Squeeze-out'-Verfahren zu. Ein vom Landgericht Hannover ernannter unabhängiger Prüfer hatte zuvor den Preis pro Aktie von 12,75 EUR bestätigt.
Mit der Eintragung des Beschlusses im Handelsregister wurde Evotec zum alleinigen Eigentümer der DeveloGen AG, welche in Evotec (Göttingen) umbenannt wurde.
Kontakt Evotec AG: Dr. Werner Lanthaler, Vorstandsvorsitzender, Tel.: +49.(0)40.56081-242, werner.lanthaler@evotec.com
24.01.2012 Veröffentlichung einer Corporate News/Finanznachricht, übermittelt durch die DGAP - ein Unternehmen der EquityStory AG. Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen. Medienarchiv unter http://www.dgap-medientreff.de und http://www.dgap.de
Sprache: Deutsch Unternehmen: Evotec AG Manfred Eigen Campus / Essener Bogen 7 22419 Hamburg Deutschland Telefon: +49 (0)40 560 81-0 Fax: +49 (0)40 560 81-222 E-Mail: info@evotec.com Internet: www.evotec.com ISIN: DE0005664809 WKN: 566480 Börsen: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
Ende der Mitteilung DGAP News-Service
http://www.finanznachrichten.de/nachrichten-2012-01/22511540…
evotec sucht aktuell sogar 9 leute und die Seite wurde auch ein wenig umgestaltet!
https://recruitment.evotec.com/Vacancy.aspx
https://recruitment.evotec.com/Vacancy.aspx
Zitat aus dem ARIVA-Forum:
http://www.ariva.de/forum/es-kann-los-gehen-352301?page=220#…
klarer-kopf: So sehe ich Evotec 2012
2
22.01.12 16:17
#5509
Ich selbst fiebere dem Jahr 2012 seid meinem einstieg 2008 bei Evotec entgegen.
Ich denke das die Performance aus Unternehmerischer sicht nicht besser sein könnte und ich habe bei meinem einstieg zwar nicht daran gezweifelt das Herr Lanthaler es schafft Evotec auf Kurs zu bringen, aber ich hatte so meine Zweifel was die Nachhaltigkeit betrifft.
Was sind aus meiner sicht die aktuell bekannten zu erwartenden Höhepunkte 2012?
Es scheinen viele hier DiaPep 277 (Typ1 Diabetes) zu unterschätzen denn es wird ca Mitte diesen Jahres wahrscheinlich ein Meilenstein ausgelöst für den finalen Abschluss der 1.Phase 3.
Die 2.Phase3 wurde bereits gestartet!!!!
Über diese Höhe des Meilensteins kann man nur spekulieren, sie dürfte aber wesendlich höher liegen als 2millionen ( bei einem Maktwert von 500Millionen)
EVT 302 (gegen Alzheimer) mit Roche.
Hier hat Evotec bereits 10Millionen Dollar als Vorabzahlung erhalten, hier wird gerade die Phase 2b Studie vorbereitet deren Start für 2012 vorgesehen ist und das den nächsten Meilenstein auslösen würde. (mögliche Meilensteine bis zu 820Millionen Dollar möglich bei einem Marktpotential von 3-5 Milliarden Euro !!!!!)
Wirkstoffforschungsallianzen mit UCB, Novartis , Böhringer Ingelheim, Genentech, ONO,CHDI, Medimmune-Astra Zeneca, Pfizer , Roche… sollte einigen unter euch zu denken geben ob Evotec interessant für Big Pharma ist oder nicht. Ich für meinen Teil halte an Evotec fest und habe bei 2,46 noch eine Anteilsaufstockung im Rahmen meiner finanziellen Situation vorgenommen.
KEINE HANDELSAUFFORDERUNG,!!! Nur meine Sichtweise zu Evotecs aktueller Situation
Was dieses Jahr noch so kommt wer weiss denn ich geh auch davon aus das auch noch neue Partnerschaften bekannt gegeben werden denn da sind ja noch interessante Entwicklungen die noch nicht verpartnert sind
http://www.ariva.de/forum/es-kann-los-gehen-352301?page=220#…
klarer-kopf: So sehe ich Evotec 2012
2
22.01.12 16:17
#5509
Ich selbst fiebere dem Jahr 2012 seid meinem einstieg 2008 bei Evotec entgegen.
Ich denke das die Performance aus Unternehmerischer sicht nicht besser sein könnte und ich habe bei meinem einstieg zwar nicht daran gezweifelt das Herr Lanthaler es schafft Evotec auf Kurs zu bringen, aber ich hatte so meine Zweifel was die Nachhaltigkeit betrifft.
Was sind aus meiner sicht die aktuell bekannten zu erwartenden Höhepunkte 2012?
Es scheinen viele hier DiaPep 277 (Typ1 Diabetes) zu unterschätzen denn es wird ca Mitte diesen Jahres wahrscheinlich ein Meilenstein ausgelöst für den finalen Abschluss der 1.Phase 3.
Die 2.Phase3 wurde bereits gestartet!!!!
Über diese Höhe des Meilensteins kann man nur spekulieren, sie dürfte aber wesendlich höher liegen als 2millionen ( bei einem Maktwert von 500Millionen)
EVT 302 (gegen Alzheimer) mit Roche.
Hier hat Evotec bereits 10Millionen Dollar als Vorabzahlung erhalten, hier wird gerade die Phase 2b Studie vorbereitet deren Start für 2012 vorgesehen ist und das den nächsten Meilenstein auslösen würde. (mögliche Meilensteine bis zu 820Millionen Dollar möglich bei einem Marktpotential von 3-5 Milliarden Euro !!!!!)
Wirkstoffforschungsallianzen mit UCB, Novartis , Böhringer Ingelheim, Genentech, ONO,CHDI, Medimmune-Astra Zeneca, Pfizer , Roche… sollte einigen unter euch zu denken geben ob Evotec interessant für Big Pharma ist oder nicht. Ich für meinen Teil halte an Evotec fest und habe bei 2,46 noch eine Anteilsaufstockung im Rahmen meiner finanziellen Situation vorgenommen.
KEINE HANDELSAUFFORDERUNG,!!! Nur meine Sichtweise zu Evotecs aktueller Situation
Was dieses Jahr noch so kommt wer weiss denn ich geh auch davon aus das auch noch neue Partnerschaften bekannt gegeben werden denn da sind ja noch interessante Entwicklungen die noch nicht verpartnert sind
Trading Spotlight
wenn ich mir mal so die internetseiten der deutschen biotechs anschaue(an der börse) fällt mir auf kaum jemand sucht mitarbeiter selbst morphosys nur zwei leute, da sticht evotec deutlich hervor !
Moin,
noch zur CureNephron Kooperation:
01/17/2012 05:06:12 PM EST -- BioWorld Insight
Evotec, Harvard Join Forces Again in Kidney Disease Pact
Evotec AG entered its second scientific discovery collaboration with Harvard
University inside a year. The company is teaming up with Harvard scientists
Andy McMahon and Ben Humphreys on an initiative called CureNephron to
identify novel targets – and drugs acting on them – that have diseasemodifying
potential in a range of kidney indications.
Financial terms were not disclosed, but the alliance has echoes of a similar
pact on diabetes, which Hamburg, Germany-based Evotec entered with
Harvard's Doug Melton last year. Each offers an alternative commercialization
pathway to straight out-licensing deals with big pharma companies. "In
essence, we are doing what, in older times, VCs would have done," Evotec
CEO Werner Lanthaler told BioWorld International.
The projects also are structured like start-ups. "CureBeta is run like an
internal venture. CureNephron will be run like an internal venture," Lanthaler
said. Evotec already has assigned a team of more than 20 staffers to
CureBeta, which is focused on therapies for beta cell regeneration in Type I
diabetes. More than 10 will assigned to CureNephron initially, and at least
three projects will be pursued.
The rationale underpinning each venture is to use Evotec's industrial
infrastructure and drug development expertise to bridge the gap between
academic science and industry. It gets science off what Lanthaler called "the
funding merry-go-round" and offers it an accelerated pathway toward
commercialization, while it gives Evotec access to leading scientists who have
developed research programs that can act as starting points for an industrialscale
screening effort.
"The biological expertise which the two guys bring into the collaboration is
probably the best academic franchise [in kidney disease] on the planet," he
said. "What they also brought to the table was their intention to keep the
effort going and not just hand it over to someone."
McMahon and Humphreys lead the kidney disease program at the Harvard
Stem Cell Institute in Cambridge, Mass., the goal of which is to understand
the biology, differentiation, maintenance, repair and diseases of the nephron,
in order to develop regenerative therapies for people with chronic kidney
disease. The industry pipeline is quite bare in that area, Lanthaler noted.
"There's not so much innovation at this stage. On the other hand, there is a
dramatic medical need."
The alliance will contemplate the development of small-molecule drugs, as
well as all forms of biologics, Lanthaler said. But it will start with an
unbiased, systematic study of disease mechanisms. "If you don't understand
the mechanism, you will never make a drug," he said.
Evotec has a research budget of €10 million (US$12.7 million) for the coming
year. It also is looking to enter similar alliances with researchers in
neurodegenerative disease and in respiratory disease. It expects to sign an
agreement in one of those areas within the next six months Lanthaler said.
At the other end of its pipeline, the company expects its partner Roche AG, of
Basel, Switzerland, to begin a Phase IIb trial of its monoamine oxidase type
B inhibitor EVT 302 later this year. The two entered a pact worth up to $830
million in up-front and milestone payments last year. (See BioWorld
International, Sep. 7, 2011.)
In May, its partners, Teva Pharmaceutical Industries Ltd., of Petach Tikva,
Israel, and Andromeda, Biotech Ltd., of Yavne, Israel, are due to report the
final data of a Phase III trial of DiaPep277 in Type I diabetes.
Top-line results, disclosed in November 2011, indicated the molecule attained
the primary endpoint of the 457-patient study. Lanthaler's view of its
prospects have improved considerably over the last 12 months. "Now I'd say
I'm very optimistic that this could be a true product," he said.
(c) 2012 Thomson BioWorld, All Rights Reserved.
Grüße
noch zur CureNephron Kooperation:
01/17/2012 05:06:12 PM EST -- BioWorld Insight
Evotec, Harvard Join Forces Again in Kidney Disease Pact
Evotec AG entered its second scientific discovery collaboration with Harvard
University inside a year. The company is teaming up with Harvard scientists
Andy McMahon and Ben Humphreys on an initiative called CureNephron to
identify novel targets – and drugs acting on them – that have diseasemodifying
potential in a range of kidney indications.
Financial terms were not disclosed, but the alliance has echoes of a similar
pact on diabetes, which Hamburg, Germany-based Evotec entered with
Harvard's Doug Melton last year. Each offers an alternative commercialization
pathway to straight out-licensing deals with big pharma companies. "In
essence, we are doing what, in older times, VCs would have done," Evotec
CEO Werner Lanthaler told BioWorld International.
The projects also are structured like start-ups. "CureBeta is run like an
internal venture. CureNephron will be run like an internal venture," Lanthaler
said. Evotec already has assigned a team of more than 20 staffers to
CureBeta, which is focused on therapies for beta cell regeneration in Type I
diabetes. More than 10 will assigned to CureNephron initially, and at least
three projects will be pursued.
The rationale underpinning each venture is to use Evotec's industrial
infrastructure and drug development expertise to bridge the gap between
academic science and industry. It gets science off what Lanthaler called "the
funding merry-go-round" and offers it an accelerated pathway toward
commercialization, while it gives Evotec access to leading scientists who have
developed research programs that can act as starting points for an industrialscale
screening effort.
"The biological expertise which the two guys bring into the collaboration is
probably the best academic franchise [in kidney disease] on the planet," he
said. "What they also brought to the table was their intention to keep the
effort going and not just hand it over to someone."
McMahon and Humphreys lead the kidney disease program at the Harvard
Stem Cell Institute in Cambridge, Mass., the goal of which is to understand
the biology, differentiation, maintenance, repair and diseases of the nephron,
in order to develop regenerative therapies for people with chronic kidney
disease. The industry pipeline is quite bare in that area, Lanthaler noted.
"There's not so much innovation at this stage. On the other hand, there is a
dramatic medical need."
The alliance will contemplate the development of small-molecule drugs, as
well as all forms of biologics, Lanthaler said. But it will start with an
unbiased, systematic study of disease mechanisms. "If you don't understand
the mechanism, you will never make a drug," he said.
Evotec has a research budget of €10 million (US$12.7 million) for the coming
year. It also is looking to enter similar alliances with researchers in
neurodegenerative disease and in respiratory disease. It expects to sign an
agreement in one of those areas within the next six months Lanthaler said.
At the other end of its pipeline, the company expects its partner Roche AG, of
Basel, Switzerland, to begin a Phase IIb trial of its monoamine oxidase type
B inhibitor EVT 302 later this year. The two entered a pact worth up to $830
million in up-front and milestone payments last year. (See BioWorld
International, Sep. 7, 2011.)
In May, its partners, Teva Pharmaceutical Industries Ltd., of Petach Tikva,
Israel, and Andromeda, Biotech Ltd., of Yavne, Israel, are due to report the
final data of a Phase III trial of DiaPep277 in Type I diabetes.
Top-line results, disclosed in November 2011, indicated the molecule attained
the primary endpoint of the 457-patient study. Lanthaler's view of its
prospects have improved considerably over the last 12 months. "Now I'd say
I'm very optimistic that this could be a true product," he said.
(c) 2012 Thomson BioWorld, All Rights Reserved.
Grüße
Die Saure-Gurken-Zeit ist vorbei: 
Durchsuchen
18.04.24 · wO Newsflash · American Express |
18.04.24 · wO Newsflash · Evotec |
18.04.24 · EQS Group AG · Evotec |
18.04.24 · Sharedeals · Evotec |
| Zeit | Titel |
|---|---|
| 18.04.24 | |
| 13.02.24 | |
| 22.01.24 | |
| 17.01.24 | |
| 08.01.24 | |
| 15.05.23 |